Cargando…
Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (CORIMUNO-ANA-1): a randomised controlled trial
BACKGROUND: Patients with COVID-19 pneumonia have an excess of inflammation and increased concentrations of cytokines including interleukin-1 (IL-1). We aimed to determine whether anakinra, a recombinant human IL-1 receptor antagonist, could improve outcomes in patients in hospital with mild-to-mode...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7825875/ https://www.ncbi.nlm.nih.gov/pubmed/33493450 http://dx.doi.org/10.1016/S2213-2600(20)30556-7 |
Ejemplares similares
-
Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): An open-label randomised controlled trial
Publicado: (2022) -
Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: A randomised clinical trial from the CORIMUNO-19 study group
por: Hermine, Olivier, et al.
Publicado: (2022) -
Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group
por: Hermine, Olivier, et al.
Publicado: (2022) -
Limit of detection of troponin discharge strategy versus usual care: randomised controlled trial
por: Carlton, Edward Watts, et al.
Publicado: (2020) -
Anakinra versus Baricitinib: Different Strategies for Patients Hospitalized with COVID-19
†
por: García-García, José A, et al.
Publicado: (2021)